The American Society of Gastrointestinal Endoscopy (ASGE) has similar recommendations for patients with BRCA1, BRCA1, and PALB2 mutations to begin screening for pancreatic cancer at the age of 50 years or 10 years younger than the youngest relative with pancreatic cancer [78]. Here, PALB2 is linked to pancreatic neoplasm.